With the Laboratory for Personalized Molecular Medicine (LabPMM®), another company joins the biotech cluster at the Hallbergmoos site. Highly specialized employees of the Invivoscribe subsidiary LabPMM® work in their new premises on site on around 600 square meters of laboratory and office space. The team focuses on clinical tests and services for cancer research and immunotherapies, in particular for testing leukemia and lymphoma. Invivoscribe has sites all over the world: in the USA, Japan, China and now also in Hallbergmoos.
LabPMM® performs clinical tests and diagnostics worldwide to support clinical trials and patient care for leading pharmaceutical companies, cancer research centers and reference laboratories. In Hallbergmoos, the company plans to grow even larger: “Our laboratory offers molecular tests to support medical diagnosis, treatment optimization and stratification as well as patient inclusion in clinical trials. With the move to Hallbergmoos, to the Skygate premises, we want to further expand our testing services and support for patient diagnosis and global clinical trials. This is the only way we can meet the testing requirements of customers and partners. The municipality of Hallbergmoos and the Rock Capital Group as the owner of Skygate have convinced us of the location,” comments Invivoscribe CEO and Chairman Dr. Jeffrey E. Miller on the move to the new premises.
The Hallbergmoos site is very familiar with the special requirements of a laboratory’s infrastructure and premises. A decisive factor for the relocation of LabPMM®. But other companies from the biotech sector have also settled here: Pieris Pharmaceuticals, Metabolon and vermicon AG. The fact that the airport community also has other infrastructural advantages will benefit the development of the biotech cluster. “From here, we can receive samples for clinical trials from all over the world without delay. The infrastructure, the available rental space, the location in the immediate vicinity of the airport, the public transport connections and the experience in the technical expansion of laboratories offer numerous advantages for biotech companies. The creation of a cluster is only natural,” Dr. Stefanie Zorbas-Seifried, Director of Clinical Operations at LabPMM® GmbH, is also convinced.
Image material © Rock Capital Group, photo Claus Uhlendorf
